We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

50 hedge funds and large institutions have $25M invested in F-star Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

7% less funds holding

Funds holding: 54 → 50 (-4)

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

66% less capital invested

Capital invested by funds: $74M → $25M (-$49M)

Holders
50
Holders Change
-4
Holders Change %
-7.41%
% of All Funds
1.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
16
Reduced
10
Closed
14
Calls
$738K
Puts
–
Net Calls
+$738K
Net Calls Change
-$1.36M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.85M
2
BI
BVF Inc
California
+$2.34M
3
Millennium Management
Millennium Management
New York
+$1.43M
4
Goldman Sachs
Goldman Sachs
New York
+$660K
5
Renaissance Technologies
Renaissance Technologies
New York
+$631K

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$5.55M
2
BlackRock
BlackRock
New York
-$3.22M
3
State Street
State Street
Massachusetts
-$1.19M
4
MAM
Morse Asset Management
Connecticut
-$918K
5
CWG
C WorldWide Group
Denmark
-$547K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$5.26M +$2.85M +106,250 +43%
BI
2
BVF Inc
California
$4.8M +$2.34M +87,500 +37%
BBA
3
Baker Bros. Advisors
New York
$2.26M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.86M -$328K -12,256 -9%
TA
5
Tiedemann Advisors
New York
$1.52M – – –
Axa
6
Axa
France
$1.4M +$55.1K +2,056 +2%
PCM
7
Parsons Capital Management
Rhode Island
$1.02M +$2.01K +75 +0.1%
SAM
8
Sectoral Asset Management
Quebec, Canada
$1.02M – – –
Millennium Management
9
Millennium Management
New York
$787K +$1.43M +53,297 New
BlackRock
10
BlackRock
New York
$751K -$3.22M -120,339 -70%
Northern Trust
11
Northern Trust
Illinois
$690K +$19K +709 +2%
Renaissance Technologies
12
Renaissance Technologies
New York
$484K +$631K +23,575 +256%
Goldman Sachs
13
Goldman Sachs
New York
$363K +$660K +24,627 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$286K -$302K -11,277 -37%
SAM
15
Silvercrest Asset Management
New York
$234K – – –
PP
16
Paloma Partners
Connecticut
$230K +$417K +15,575 New
HP
17
Hikari Power
Japan
$226K +$52.2K +1,950 +15%
PCA
18
Private Capital Advisors
Connecticut
$193K – – –
Morgan Stanley
19
Morgan Stanley
New York
$166K +$153K +5,694 +103%
Deutsche Bank
20
Deutsche Bank
Germany
$161K +$178K +6,649 +152%
FI
21
Fosun International
China
$122K – – –
JP Morgan Chase
22
JP Morgan Chase
New York
$98K +$44K +1,641 +35%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$91K +$165K +6,171 New
CC
24
Caxton Corporation
New Jersey
$88K +$696 +26 +0.4%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$73K – – –
1
2 3

FSTX Hedge Fund Activity: Q2 2019 in Review

50 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2019, worth a combined $25M — down 66% from $74M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of FSTX and 12 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 16 added.

The largest buyer was Adage Capital Partners, adding an estimated $2.85M. The largest seller was Jennison Associates, exiting entirely with an estimated $5.55M sold.

  • 50 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2019, down from 54 in Q1 2019.
  • Funds reported $25M of F-star Therapeutics, Inc. Common Stock stock for Q2 2019, down 66% quarter-over-quarter.
  • 12 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2019 and 14 closed out, a net change of -2 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2019 was Adage Capital Partners, an estimated $2.85M added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2019 was Jennison Associates, an estimated $5.55M sold.

Based on aggregated 13F filings for Q2 2019.